Modality
Nanobody
MOA
AuroraAi
Target
HER2
Pathway
PD-1/PD-L1
TTR AmyloidosisCRCSCLC
Development Pipeline
Preclinical
~Sep 2019
→ ~Dec 2020
Phase 1
Mar 2021
→ Jan 2028
Phase 1Current
NCT03060655
2,389 pts·SCLC
2021-03→2028-01·Recruiting
2,389 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-011.8y awayPh2 Data· SCLC
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P1/2
Recruit…
Catalysts
Ph2 Data
2028-01-01 · 1.8y away
SCLC
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03060655 | Phase 1/2 | SCLC | Recruiting | 2389 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| ILM-2412 | Illumina | Phase 3 | PLK4 |